Bausch Health Cos (BHC) Competitors

$5.34 -0.04 (-0.65%)

As of 11:09 AM Eastern

BHC vs. PCVX, CYTK, KRYS, NUVL, and IBRX

Should you be buying Bausch Health Cos stock or one of its competitors? The main competitors of Bausch Health Cos include Vaxcyte (PCVX), Cytokinetics (CYTK), Krystal Biotech (KRYS), Nuvalent (NUVL), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.

How does Bausch Health Cos compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Vaxcyte has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Vaxcyte has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Vaxcyte's return on equity of -32.51% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

In the previous week, Vaxcyte had 8 more articles in the media than Bausch Health Cos. MarketBeat recorded 9 mentions for Vaxcyte and 1 mentions for Bausch Health Cos. Vaxcyte's average media sentiment score of 0.65 beat Bausch Health Cos' score of 0.50 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch Health Cos	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte presently has a consensus price target of $86.00, suggesting a potential upside of 59.93%. Bausch Health Cos has a consensus price target of $8.00, suggesting a potential upside of 49.95%. Given Vaxcyte's stronger consensus rating and higher possible upside, equities research analysts plainly believe Vaxcyte is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Bausch Health Cos has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Bausch Health Cos	$10.27B	0.19	$157M	-$3.24	N/A

Summary

Vaxcyte beats Bausch Health Cos on 9 of the 15 factors compared between the two stocks.

How does Bausch Health Cos compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

78.7% of Bausch Health Cos shares are held by institutional investors. 2.6% of Cytokinetics shares are held by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cytokinetics has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

In the previous week, Cytokinetics had 40 more articles in the media than Bausch Health Cos. MarketBeat recorded 41 mentions for Cytokinetics and 1 mentions for Bausch Health Cos. Cytokinetics' average media sentiment score of 0.62 beat Bausch Health Cos' score of 0.50 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	15 Very Positive mention(s)	2 Positive mention(s)	17 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch Health Cos	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bausch Health Cos has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	105.73	-$784.96M	-$6.84	N/A
Bausch Health Cos	$10.27B	0.19	$157M	-$3.24	N/A

Bausch Health Cos has a net margin of -11.47% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

Cytokinetics currently has a consensus price target of $98.55, suggesting a potential upside of 31.74%. Bausch Health Cos has a consensus price target of $8.00, suggesting a potential upside of 49.95%. Given Bausch Health Cos' higher probable upside, analysts clearly believe Bausch Health Cos is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.82
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Bausch Health Cos beats Cytokinetics on 10 of the 17 factors compared between the two stocks.

How does Bausch Health Cos compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Krystal Biotech has a net margin of 53.92% compared to Bausch Health Cos' net margin of -11.47%. Krystal Biotech's return on equity of 19.25% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

Krystal Biotech currently has a consensus price target of $324.11, suggesting a potential upside of 3.38%. Bausch Health Cos has a consensus price target of $8.00, suggesting a potential upside of 49.95%. Given Bausch Health Cos' higher possible upside, analysts plainly believe Bausch Health Cos is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Krystal Biotech has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

In the previous week, Krystal Biotech had 21 more articles in the media than Bausch Health Cos. MarketBeat recorded 22 mentions for Krystal Biotech and 1 mentions for Bausch Health Cos. Krystal Biotech's average media sentiment score of 0.80 beat Bausch Health Cos' score of 0.50 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	7 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch Health Cos	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Krystal Biotech has higher earnings, but lower revenue than Bausch Health Cos. Bausch Health Cos is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	23.75	$204.83M	$7.48	41.91
Bausch Health Cos	$10.27B	0.19	$157M	-$3.24	N/A

Summary

Krystal Biotech beats Bausch Health Cos on 13 of the 16 factors compared between the two stocks.

How does Bausch Health Cos compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Nuvalent presently has a consensus price target of $137.25, indicating a potential upside of 33.49%. Bausch Health Cos has a consensus price target of $8.00, indicating a potential upside of 49.95%. Given Bausch Health Cos' higher probable upside, analysts plainly believe Bausch Health Cos is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.88
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Nuvalent had 15 more articles in the media than Bausch Health Cos. MarketBeat recorded 16 mentions for Nuvalent and 1 mentions for Bausch Health Cos. Nuvalent's average media sentiment score of 0.61 beat Bausch Health Cos' score of 0.50 indicating that Nuvalent is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch Health Cos	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvalent has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

Bausch Health Cos has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Bausch Health Cos	$10.27B	0.19	$157M	-$3.24	N/A

Nuvalent has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Nuvalent's return on equity of -41.73% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-41.73%	-36.87%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are owned by institutional investors. 10.2% of Nuvalent shares are owned by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Nuvalent beats Bausch Health Cos on 8 of the 15 factors compared between the two stocks.

How does Bausch Health Cos compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Bausch Health Cos has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$140.98M	59.40	-$351.40M	-$0.85	N/A
Bausch Health Cos	$10.27B	0.19	$157M	-$3.24	N/A

In the previous week, ImmunityBio had 57 more articles in the media than Bausch Health Cos. MarketBeat recorded 58 mentions for ImmunityBio and 1 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.50 beat ImmunityBio's score of 0.02 indicating that Bausch Health Cos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	5 Very Positive mention(s)	5 Positive mention(s)	35 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Neutral
Bausch Health Cos	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmunityBio presently has a consensus price target of $14.20, indicating a potential upside of 77.59%. Bausch Health Cos has a consensus price target of $8.00, indicating a potential upside of 49.95%. Given ImmunityBio's stronger consensus rating and higher possible upside, equities research analysts clearly believe ImmunityBio is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

ImmunityBio has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 69.5% of ImmunityBio shares are held by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Bausch Health Cos has a net margin of -11.47% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-64.93%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

Summary

ImmunityBio beats Bausch Health Cos on 9 of the 17 factors compared between the two stocks.

Get Bausch Health Cos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHC vs. The Competition

Export

Metric	Bausch Health Cos	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$1.99B	$5.88B	$6.24B	$22.77B
Dividend Yield	N/A	0.69%	2.78%	4.03%
P/E Ratio	-1.65	7.61	20.67	28.59
Price / Sales	0.19	23.97	547.41	103.96
Price / Cash	0.79	8.26	27.81	19.21
Price / Book	5.23	4.10	9.59	4.60
Net Income	$157M	$118.49M	$3.54B	$1.07B
7 Day Performance	-5.49%	-3.02%	-0.45%	-1.08%
1 Month Performance	-4.99%	2.63%	5.68%	2.93%
1 Year Performance	11.49%	126.39%	38.47%	23.96%

Bausch Health Cos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHC Bausch Health Cos	2.3515 of 5 stars	$5.34 -0.7%	$8.00 +50.0%	+17.7%	$1.99B	$10.27B	N/A	20,300
PCVX Vaxcyte	2.7172 of 5 stars	$58.49 +2.7%	$86.00 +47.0%	+73.3%	$8.22B	N/A	N/A	160	Earnings Report
CYTK Cytokinetics	2.9604 of 5 stars	$66.05 +4.3%	$90.55 +37.1%	+135.3%	$7.87B	$88.04M	N/A	250	Earnings Report Analyst Upgrade
KRYS Krystal Biotech	2.9687 of 5 stars	$284.93 +7.1%	$326.25 +14.5%	+136.6%	$7.83B	$389.13M	41.60	210	Analyst Upgrade High Trading Volume
NUVL Nuvalent	3.1137 of 5 stars	$102.62 +3.6%	$137.25 +33.7%	+49.7%	$7.79B	N/A	N/A	40	Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BHC) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bausch Health Cos (BHC) Competitors

BHC vs. PCVX, CYTK, KRYS, NUVL, and IBRX

How does Bausch Health Cos compare to Vaxcyte?

Summary

How does Bausch Health Cos compare to Cytokinetics?

Summary

How does Bausch Health Cos compare to Krystal Biotech?

Summary

How does Bausch Health Cos compare to Nuvalent?

Summary

How does Bausch Health Cos compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC vs. The Competition

Bausch Health Cos Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bausch Health Cos (BHC) Competitors

BHC vs. PCVX, CYTK, KRYS, NUVL, and IBRX

How does Bausch Health Cos compare to Vaxcyte?

Do insiders and institutionals hold more shares of PCVX or BHC?

Which has more volatility & risk, PCVX or BHC?

Is PCVX or BHC more profitable?

Does the media refer more to PCVX or BHC?

Do analysts prefer PCVX or BHC?

Which has higher valuation and earnings, PCVX or BHC?

Summary

How does Bausch Health Cos compare to Cytokinetics?

Do institutionals & insiders believe in CYTK or BHC?

Which has more volatility & risk, CYTK or BHC?

Does the media favor CYTK or BHC?

Which has higher earnings and valuation, CYTK or BHC?

Is CYTK or BHC more profitable?

Do analysts rate CYTK or BHC?

Summary

How does Bausch Health Cos compare to Krystal Biotech?

Is KRYS or BHC more profitable?

Do analysts recommend KRYS or BHC?

Which has more risk and volatility, KRYS or BHC?

Does the media refer more to KRYS or BHC?

Do institutionals and insiders believe in KRYS or BHC?

Which has preferable earnings and valuation, KRYS or BHC?

Summary

How does Bausch Health Cos compare to Nuvalent?

Do analysts rate NUVL or BHC?

Does the media favor NUVL or BHC?

Which has more risk and volatility, NUVL or BHC?

Which has stronger valuation & earnings, NUVL or BHC?

Is NUVL or BHC more profitable?

Do institutionals & insiders believe in NUVL or BHC?

Summary

How does Bausch Health Cos compare to ImmunityBio?

Which has higher valuation and earnings, IBRX or BHC?

Does the media favor IBRX or BHC?

Do analysts rate IBRX or BHC?

Which has more risk & volatility, IBRX or BHC?

Do insiders and institutionals have more ownership in IBRX or BHC?

Is IBRX or BHC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC vs. The Competition

Bausch Health Cos Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools